Physician profile
Robert J Gianotti
NPI 1356509574
$58,051.21
in general payments reported to CMS, 2019-2025
18 companies · $886 in 2025
The $886 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,604 · 2020: $4,047 · 2021: $7,718 · 2022: $17K · 2023: $17K · 2024: $812 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $2,791 · Travel and Lodging: $839 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,545.00 |
| Food and Beverage | $2,790.80 |
| Travel and Lodging | $839.06 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $55,360.75 | 2019-2025 | |
| Janssen Biotech, INC. | $896.42 | 2019-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $765.00 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $218.46 | 2022-2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $184.95 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $141.88 | 2019-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $128.34 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.40 | 2019 | |
| Intercept Pharmaceuticals, INC. | $49.54 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $40.56 | 2022-2023 | Rebyota |
| Boston Scientific Corporation | $34.17 | 2023 | Resolution 360 Clip |
| Lilly USA, LLC | $23.40 | 2025 | Omvoh |
| Genzyme Corporation | $20.82 | 2024 | |
| Daiichi Sankyo INC. | $16.97 | 2019 | |
| Celltrion USA INC. | $16.67 | 2025 | Vegzelma |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endogastric Solutions, INC | $16.32 | 2019 | |
| Erbe USA INC | $13.61 | 2021 | |
| Allergan, INC. | $12.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gianotti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.